Synthesis, molecular docking and antimalarial activity of phenylalanine-glycine dipeptide bearing sulphonamide moiety

•Sulphonamide compounds had been used as antibacterial agents, anticancer, antioxidant, antimalarial, Human Carbonic Anhydrases inhibitor, anti-inflammatory.•Dipeptides involve the combination of two same or different amino acids in a compound for peptide bond.•The synthesis involved the use of pept...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular structure 2021-12, Vol.1246, p.131201, Article 131201
Main Authors: Aronimo, Babatunde S., Okoro, Uchechukwu C., Ali, Rafat, Ibeji, Collins U., Ezugwu, James A., Ugwu, David I.
Format: Article
Language:English
Subjects:
Antimalarial
Dipeptide Sulphonamide
Glycine
Molecular docking
Phenylalanine
Synthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Sulphonamide compounds had been used as antibacterial agents, anticancer, antioxidant, antimalarial, Human Carbonic Anhydrases inhibitor, anti-inflammatory.•Dipeptides involve the combination of two same or different amino acids in a compound for peptide bond.•The synthesis involved the use of peptide coupling reagents.•The synthesized dipeptides possess antimalarial. Ten novel phenylalanine-glycine dipeptide sulphonamide conjugate were synthesized and characterized using 1HNMR, 13CNMR, FTIR and HRMS spectroscopic techniques. The in silico studies predicted better interactions of compounds with target protein residues and a higher dock score in comparison with standard drugs. The in vivo antimalarial study, hematological study, liver and kidney function test were evaluated on the synthesized compounds. Compounds 7h, 7i and 7j inhibited the parasite by 34.5–60.2% on day 4 of after-treatment exposure. Compound 7j inhibited the multiplication of the parasite by 60.2% on day 4 of after-treatment which was comparable with that of the standard drug with 68.8% inhibition at same day of after-treatment exposure. [Display omitted]
ISSN:0022-2860
1872-8014
DOI:10.1016/j.molstruc.2021.131201